> The Global Rethinkers > Life sciences innovation

Life sciences innovation

The life sciences and pharmaceutical industries have incredible potential for the future of humankind. We work with many leading figures, and our lawyers are at the cutting edge in supporting our clients.


get in touch

Dr Bea Bakshi

Super-charging the fight against cancer, Dr Bea Bakshi set up C the Signs to use the power of data to diagnose cancer at its earliest stages, when it can be treated more successfully. Working on the frontline in UK hospitals, Bea repeatedly saw the heart-breaking impact of late diagnosis. In our FT interview series, Bea talks candidly about her experience and how, alongside co-founder Dr Miles Payling, they are helping patients beat cancer.
  FT interview | Bea Bakshi
doctor

Partnering for success: charities at the forefront of scientific innovation

Find Out More

The new Charities Bill: endowment changes and opportunities in science innovation

Find Out More
trees growing in a vertical farm

Can agritech really transform the future of food?

Find Out More

Clients include:

Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing RNA interference therapeutics that 'silences' Messenger RNAs implicated in the cause of diseases. Alnylam delivered the world's first approved RNAi therapeutic treatment in 2018 and has developed three other first-in-class RNAi-based medicines.
Omega Therapeutics logo

Omega Therapeutics

Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines designed to controllably modulate gene expression to treat or cure diseases.
Fulcrum Therapeutics logo

Fulcrum Therapeutics

Fulcrum Therapeutics specialises in developing treatments for genetic diseases that are largely overlooked by mainstream medicine. By adapting gene expression, disorders can be treated at their root cause.
Medovate logo

Medovate

Medovate works collaboratively with clinical innovators and the NHS to develop, manufacture and bring to market new medical devices to improve patient safety and care. 
Kynos Therapeutics logo

Kynos Therapeutics

Kynos Therapeutics is developing an innovative portfolio of first-in-class medicines where there is an unmet medical need for new therapies. Their medicines block the action of KMO - a key enzyme at the interface of inflammation, immunity and metabolism.
Global Access Dx (GADx) logo

Global Access Dx (GADx)

GADx is a leading developer and manufacturer of advanced lateral flow and rapid diagnostic technologies. Leveraging their core technology platforms, they work with governments and international organisations, reinvesting their profits to deliver high quality and affordable diagnostics.
 

Our team

Thomas  Meyers

Thomas Meyers

Partner | Boston

Thomas Meyers

Partner | Boston

Intellectual property

Zachary D. Hyde

Zachary D. Hyde

Partner | Boston

Zachary D. Hyde

Partner | Boston

Intellectual property

Christopher Cowles, Ph.D.

Christopher Cowles, Ph.D.

Partner | Boston

Christopher Cowles, Ph.D.

Partner | Boston

Intellectual property and technology

Susanna Stanfield

Susanna Stanfield

Partner | Cambridge

Susanna Stanfield

Partner | Cambridge

Corporate

Richard Penfold

Richard Penfold

Partner | London

Richard Penfold

Partner | London

Intellectual property and technology

Richard B. Emmons, Ph.D.

Richard B. Emmons, Ph.D.

Partner | Boston

Richard B. Emmons, Ph.D.

Partner | Boston

Intellectual property and technology

John Serio

John Serio

Partner | Boston

John Serio

Partner | Boston

Intellectual property and technology

Jonathan Kok

Jonathan Kok

Partner | Singapore

Jonathan Kok

Partner | Singapore

Technology and Intellectual Property

James Shaw

James Shaw

Partner | London

James Shaw

Partner | London

Corporate

The Global Rethinkers

We're getting behind some of the founders and innovators who are changing our world. Check out our hub to find out more.

Global Rethinkers